Last reviewed · How we verify
NPC-09
NPC-09 is a small molecule that targets the SGLT2 receptor.
NPC-09 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | NPC-09 |
|---|---|
| Also known as | Aceneuramic acid tablets, Aceneuramic acid matching placebo |
| Sponsor | Nobelpharma |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
NPC-09 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
- Genital amputations
- Increased risk of acute kidney injury
Key clinical trials
- Efficacy Confirmation Study of NPC-09 (PHASE3)
- Pharmacokinetic Study on N-acetylneuraminic Acid (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPC-09 CI brief — competitive landscape report
- NPC-09 updates RSS · CI watch RSS
- Nobelpharma portfolio CI